MAP2K3: Regulating Cell Growth and The Cell Cycle (G5606)

Target Name: MAP2K3

NCBI ID: G5606

MAP2K3

MAP2K3: Regulating Cell Growth and The Cell Cycle

MAP2K3, also known as Mitogen-activated protein kinase kinase 3, is a protein that plays a crucial role in cell signaling pathways. It is a member of the MAPK family, which includes several related proteins that play a role in regulating cell proliferation, differentiation , and survival. One of the most significant functions of MAP2K3 is its role in the regulation of cell growth and the cell cycle.

MAP2K3 is a 21-kDa protein that is expressed in most tissues of the body. It is primarily localized to the cytoplasm of cells, where it can interact with several other proteins to regulate various cellular processes. One of the most well-known functions of MAP2K3 is its role in the regulation of cell growth and the cell cycle.

MAP2K3 plays a critical role in the regulation of cell growth by inhibiting the activity of the cell's growth factor, PDGF. PDGF is a protein that is produced by the liver and other cells in the body, and it plays a vital role in the regulation of cell growth, differentiation, and survival. However, abnormally high PDGF levels can lead to tumorigenesis and cell proliferation. Therefore, the role of MAP2K3 in controlling cell growth and inhibiting tumorigenesis has received widespread attention.

MAP2K3 can also interact with other proteins such as CDK4, CDK6, p21 and p53. Together, these proteins regulate the cell cycle, including G1, S, and G2 phases. In the G1 phase, MAP2K3 interacts with CDK4 and CDK6 to promote cells to enter the S phase. During S phase, MAP2K3 interacts with p21 to prevent cells from entering G2 phase. In the G2 phase, MAP2K3 interacts with p53 to promote cells to enter the M phase. These interactions enable MAP2K3 to play a critical role in the cell cycle.

In addition, MAP2K3 is also involved in regulating apoptosis. Apoptosis is an important form of cell death that plays a key role in maintaining tissue homeostasis and clearing damaged cells. MAP2K3 can regulate the initiation and execution of apoptosis. For example, MAP2K3 can bind to Bcl-2 protein and inhibit its binding to PDGF, thereby inhibiting cell apoptosis. This inhibitory effect is critical for maintaining tissue and organ homeostasis.

In addition, MAP2K3 is also closely related to the occurrence and development of many diseases. For example, MAP2K3 is involved in the development of various cancers, including lung cancer, liver cancer, breast cancer, etc. The expression level of MAP2K3 is also related to the occurrence and development of various diseases, such as diabetes, obesity, and neurodegenerative diseases. Therefore, MAP2K3, as a potential drug target or biomarker, has broad application prospects in disease diagnosis and treatment.

In summary, MAP2K3 is an important protein that plays a key role in cell signaling pathways. The activity and function of MAP2K3 can be regulated in various ways, including interacting with PDGF, CDK4, CDK6, p21 and p53, participating in apoptosis, and being closely related to the occurrence and development of various diseases. Therefore, MAP2K3, as a drug target or biomarker, has broad application prospects in disease diagnosis and treatment.

Protein Name: Mitogen-activated Protein Kinase Kinase 3

Functions: Dual specificity kinase. Is activated by cytokines and environmental stress in vivo. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in the MAP kinase p38. Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14

The "MAP2K3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP2K3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets